GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study

GSK plc GSK announced headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy,…

#gskplc #gsk #rubyengoten6 #rsvvaccinemarket #mss